We investigated the level of minimal residual disease (MRD) in 26 children with B-lineage acute lymphoblastic leukemia (ALL) after intensive induction therapy. A quantitative semi-nested polymerase chain reaction (PCR) detecting the clone-specific rearranged immunoglobulin heavy chain genes was developed to improve sensitivity and specificity of amplification. In all patients, one leukemic cell could be detected in a background of 10 5 normal blood mononuclear cells. All patients investigated were in complete remission at the end of induction therapy as evaluated by morphologic criteria. Nineteen patients (73%) had no detectable residual leukemic cells using the sensitive semi-nested PCR. Seven patients (27%) were PCR positive. Three had a low level (Ͻ2 ؋ 10 ؊5 leukemic cells per bone marrow cell), while four patients had a high level (Ͼ2 ؋ 10 ؊5 ) of detectable residual leukemic cells. All patients with low or undetectable levels of residual leukemia remained in complete remission at a median of 63 months from diagnosis (range 40-80 months), while all four patients with a high level of residual leukemia subsequently relapsed at a median of 21 months from diagnosis (range 13-37 months). The patient groups with undetectable or low, and high level of MRD did not differ significantly in other clinical or genetic features with prognostic significance. We conclude that the level of MRD at the end of the intensive induction therapy period is predictive of outcome in childhood B lineage ALL. If confirmed by large prospective studies, the level of MRD might be useful in stratifying patients into high and low risk categories.
Introduction
The cure rate in childhood acute lymphoblastic leukemia (ALL) with current protocols is more than 70%. 1 However, up to 30% of children with ALL will subsequently relapse. 2 Generally, it is assumed that residual leukemic cells that survive under chemotherapy are responsible for this relapse. At diagnosis, a patient with ALL harbors approximately 10 12 leukemic cells. 3 After induction therapy at least 95% of all children with ALL achieve remission. 1 However, this means only that the percentage of leukemic cells in the bone marrow is less than 5% as evaluated by morphologic criteria. The patient can still harbor 10 10 leukemic cells in the body. Most B-lineage ALLs are characterized by a unique immunoglobulin heavy chain gene rearrangement. 4 This rearrangement varies enormously due to the joining of different variable (V), diversity (D), and joining (J) gene segments. During two successive recombinations, D to J and V to D-J joining, nucleotides can be deleted from the germline gene segments by exonuclease activity. In addition, non-templatederived nucleotides (N) can be added by the enzyme terminal deoxynucleotidyl transferase. 5 Somatic mutation in any of these gene segments leads to further diversity. 6 This process generates a hypervariable sequence known as the complementarity determining region III (CDR III) that we have used as a clone-specific marker for the detection of minimal residual disease (MRD) in B-lineage ALL.
The measurement of residual leukemia at the end of induction therapy gives physicians information about the residual leukemic burden that has to be treated during further chemotherapy. In addition, residual leukemia at the end of induction therapy is a marker of in vivo sensitivity of leukemic cells to chemotherapy. The data in the literature are controversial about the predictive value of residual leukemia at the end of induction therapy. Some authors 7, 8 have found a correlation between the level of MRD and the relapse rate, whereas others 9, 10 reported that almost all children had residual leukemic cells at the end of induction therapy. In the latter two studies, there was no association between MRD level and clinical outcome. Here, we report the prognostic significance of residual leukemia using a sensitive, quantitative, seminested polymerase chain reaction (PCR) assay. Our findings indicate that the level of MRD at the end of induction therapy strongly predicts outcome in childhood B-lineage ALL.
Materials and methods

Patients and treatment
Patients enrolled in St Jude Children's Research Hospital protocols Total XII and Total XIIIA (15 November 1989 and 7 September 1993) who achieved an initial complete remission at least 3 years ago were eligible for this study. The other criteria for enrollment in this retrospective study included a diagnosis of B-lineage ALL, and the availability of DNA from diagnosis and day 43 bone marrow aspirates. Of the 190 children enrolled during the almost 4-year time period who had B-lineage ALL, 32 (18%) were available for study based on availability of DNA. Of the 32 patients, 26 patients were studied for MRD, while the remaining six patients were unable to be studied for the reasons described in the results. The patient features are described in Table 1 . Seventeen patients were treated according to St Jude Total Therapy Study XII, 11 and nine patients according to St Jude Total Therapy Study XIIIA. 12, 13 Briefly, the intensive six-drug induction therapy consisted of prednisone, vincristine, asparaginase, daunorubicin, teniposide and cytarabine for 29 days, followed by a 14-day recovery period before the 'end of induction' bone marrow at day 43. In Total Therapy Study XIIIA the epipodophyllotoxin teniposide was replaced by etoposide. All patients investigated were morphologically in complete remission at the end of induction therapy.
This investigation was approved by the Institutional Review 676 Board, and informed consent was obtained from all patients and their parents, as appropriate.
DNA extraction, cloning and sequencing Samples were obtained from bone marrow aspirates that were performed at diagnosis and on day 43. Mononuclear cells were purified by Ficoll-Hypaque (Sigma, St Louis, MO, USA) density gradients (density, Ͼ1.077 g/ml). At diagnosis, the portion of leukemic cells was greater than 80% of the mononuclear cells from bone marrow. Genomic DNA was extracted from mononuclear cells by the method of Wigler et al. 14 Amplification of rearranged immunoglobulin heavy chain genes was performed essentially as described by Deane and Norton 15 using a panel of seven V H family-specific primers complementary to the framework 1 region (FR1) together with a universal J H primer (J H U). Primers were synthesized on an Applied Biosystems 3948 DNA Synthesizer (Applied Biosystems, Foster City, CA, USA) and purified from a 20% ureacontaining polyacrylamide gel. The PCR conditions have been described previously. 16 To purify the PCR product for cloning, amplified DNA was run on a 2% NuSieve GTG agarose gel (FMC, Rockland, ME, USA) and the ethidium bromide-stained band was located and excised. Agarose was removed by digestion with Beta-agarase (New England Biolabs, Beverly, MA, USA), and the PCR product was cloned by ligation directly to the pGEM-T vector (Promega, Madison, WI, USA). White colonies were picked and grown in 2.0 ml of Superbroth. Plasmid DNA was prepared by the boiling method of Holmes and Quigley 17 and was sequenced using the T7 and SP6 primers as described in the Sequenase 2.0 protocol (Amersham, Cleveland, OH, USA). V H , D and J H sequences were identified using the sequence analysis software Wisconsin Package Version 9.0 (Genetics Computer Group, Madison, WI, USA) and by comparison with published sequences. [18] [19] [20] Detection of MRD Clone-specific primers complementary to the D-N-J sequence and N-D-N sequence were designed for each patient. These primers were also synthesized on an Applied Biosystems 3948 DNA Synthesizer and purified as described above. A twostage PCR strategy using a semi-nested approach was developed to improve sensitivity and specificity of amplification.
PCR was performed using 500 ng DNA and 2.5 units of Taq DNA polymerase (Promega) in a 50 l reaction, which contained 10 mmol/l Tris-HCl (pH 8.8), 75 mmol/l KCl, 1.5 mmol/l MgCl 2 , 0.1% Triton X-100, 50 mol/l each dATP, dGTP, dCTP, dTTP and 200 ng of each primer. Samples were subjected to an initial 5 min denaturation at 94°C followed by 25 cycles of 30 s denaturation at 94°C, 30 s annealing at the empirically determined temperature optimum for each primer pair, and 30 s extension at 72°C in a Peltier Thermal Cycler, model PTC-200 (MJ Research, Watertown, MA, USA). A final 10 min extension at 72°C was performed at the end of the PCR amplification. The amplified DNA from the first round was diluted 1:100 and 1 l was used as the template for the second round. The PCR conditions for the second round were the same as described above, except that 45 cycles were performed. We carefully optimized the annealing temperatures in both rounds until we achieved the highest sensitivity and specificity. In both rounds, the V H FR1 family-specific primer specific for the patient rearrangement was used usually with the J H U primer for the first round, and the D-N-J specific primer or N-D-N specific primer for the second round. In cases of insufficient sensitivity using the J H U primer for the first round, the D-N-J specific primer was used for the first round and the N-D-N specific primer for the second round. PCR products were analyzed by electrophoresis on a 3% Ultra Pure agarose gel (Life Technologies, Gaithersburg, MD, USA).
The sensitivity was established by making serial 10-fold dilutions of leukemic DNA into DNA obtained from pooled peripheral blood mononuclear cells until no PCR product was observed. 21 At least three replicates of each dilution were subjected to PCR amplification. Specificity was confirmed using normal peripheral blood DNA and sterile water instead of leukemic DNA as the template in the PCR. To avoid contamination in the PCR we followed the procedures recommended by Kwok and Higuchi. 22 Absolute quantitation of MRD was achieved by limiting dilution analysis with 10 replicates and Poisson statistics as described by Simmonds et al. 23 
Statistical analysis
Fisher's exact test was used to compare the distributions of clinical and genetic features of patients investigated for MRD and other B-lineage ALL patients enrolled on protocols at St Jude during the same period. The same test was used to compare these features between patients with low or undetectable levels of MRD and those with high levels of MRD. Relapsefree survival time was calculated as the time from diagnosis to the time of a leukemic relapse for those who had such an event, or to the time of death, second malignancy, or date of last contact for patients who were considered censored. Relapse-free survival experiences were estimated by the Kaplan-Meier 24 method and differences in the distribution were compared between the two MRD groups with the exact logrank test statified by study.
25
Results
Patient population
There were 11 male and 15 female patients with a median age of 5 years (range 1-15 years), and a median white blood cell (WBC) count of 5.7 × 10 9 /l (range 0.9-271.0 × 10 9 /l). All patients had a precursor-B cell immunophenotype. The presenting features of the 26 patients we studied including age, WBC count, DNA index, 9;22 translocation and TEL rearrangement were representative, and did not differ significantly from all children treated for B-lineage ALL at St Jude (Table 2; Fisher's exact test, P Ͼ 0.300). None of the patients had the t(1;19) or t(4;11) chromosomal translocation, while two patients (patient Nos 1 and 25) had the translocation t(9;22) associated with a poor prognosis. [26] [27] [28] Sensitivity of MRD detection
Residual leukemia at the end of induction therapy was investigated in 26 patients (81%) of the 32 patients eligible for this study. The reasons for exclusion of the other six patients were inability to obtain monoclonal immunoglobulin heavy chain gene rearrangement from diagnostic marrow in four patients (13%) and lack of specificity or sensitivity of the clone-specific primers in two patients (6%). In all patients investigated, one leukemic cell could be detected in a background of 10 5 normal blood mononuclear cells as demonstrated in Figure 1 . The semi-nested PCR was able to detect one to two copies of the target leukemic CDRIII sequence at the 10 −5 dilution (the total amount of DNA in each PCR reaction was 500 ng, three replicates were done, and a human diploid cell contains 6 pg of DNA). 29 To achieve this high sensitivity it was necessary to use different primer combinations. The V H FR1 family-specific primer was used with the J H U primer for the first round and with the D-N-J specific primer (33%) or the N-D-N specific primer (38%) for the second round. Alternatively, the D-N-J specific primer was used for the first round and the N-D-N specific primer for the second round (29%) when insufficient sensitivity was observed.
MRD at the end of induction therapy
Nineteen patients (73%) had no detectable residual leukemic cells at the end of induction therapy using the described sensitive semi-nested PCR. This means that the level of MRD was less than one detectable leukemic cell in 10 5 bone marrow cells. The amplifiability of the DNA samples was ascertained using primers derived from the second exon of the N-ras gene as described previously. 30 Seven patients (27%) were PCR positive. Three had a low level (Ͻ2 × 10 −5 leukemic cells per bone marrow cell), while four patients had a high level (Ͼ2 × 10 −5 ) of MRD ( Table 1 ). The cut point to distinguish between a high and a low level of MRD was empirically selected after examining the outcome of these patients as described below, but is similar to the level chosen by Brisco and co-workers. 
Outcome
The level of MRD at the end of induction therapy in relation to outcome is shown in Figure 2 . All patients with low or Demonstration of detection of residual leukemia after intensive induction therapy in three different patients with undetectable (A), low (B), and high (C) levels of MRD. Samples of DNA from bone marrow were amplified using semi-nested PCR and analyzed by electrophoresis on 3% agarose gels. Serial 10-fold dilutions of leukemic DNA from bone marrow at diagnosis were made in DNA from normal blood mononuclear cells demonstrating a sensitivity of 10 ). Normal PBL DNA and water served as negative controls. We used pBSKS(+)/HpaII as molecular weight standard (M). Two bands are visible in most lanes. The top band is the gene rearrangement and the bottom band is unincorporated primers.
undetectable levels of residual leukemia remained in complete remission without relapse at a median of 63 months (range 40-80 months) ( Table 1) nancies. All four children with a high level of residual leukemia subsequently relapsed between 13 and 37 months (Table  1) . Interestingly, the patient with highest MRD (No. 25) had the shortest remission duration, while the patient with lowest MRD (No. 23) had the longest remission duration until relapse. The patient groups with undetectable or low, and high level of MRD did not differ significantly in features with known prognostic significance at diagnosis as shown in Table  3 . However, a greater proportion of patients with age greater than 10 years (50% vs 4.5%) and patients with hyperleukocytosis (50% vs 4.5%) were found in the high MRD group (P = 0.052). Figure 3 shows the Kaplan-Meier plots of relapsefree survival since diagnosis for all patients in this study. All patients with low or undetectable levels of MRD remained in complete remission with a median follow-up of 5.25 years, whereas all patients with high levels of MRD subsequently relapsed. The two groups differed significantly in both relapsefree (P Ͻ 0.001) and event-free survival (P Ͻ 0.001) experiences. , n = 4). The difference in these two curves was statistically significant (P Ͻ0.001) as evaluated by means of the logrank test. Tick marks characterize patients who remained in complete remission at the time of the last follow-up visit. Tick marks with bullets designate the three patients with low level of MRD.
Discussion
In this study, we investigated whether the level of MRD at the end of induction therapy predicts outcome in childhood Blineage ALL. The DNA used was obtained from fresh, viable, Ficoll-Hypaque purified bone marrow cells whereas, in some previous studies, DNA was extracted from stored bone marrow slides. 7, 8 The disadvantage of DNA extracted from slides is that only a small amount is obtained and possible degradation impairs the amplifiability. 7 In our study, a monoclonal immunoglobulin heavy chain gene rearrangement was detected in 28 of 32 patients (87%). The seven V H FR1 familyspecific primers we used, as described by Deane and Norton, 15 are more efficient than a single V H FR3 primer because of 3Ј V H region deletion and/or base mismatches that prevent efficient priming from the V H FR3 primer target sequence. 31 The failure to obtain a monoclonal immunoglobulin heavy chain gene rearrangement in our study can be caused by somatic mutations in the FR1 region, 31 by D-J H recombinations, 32 or by 14q32 translocations. 33 We have developed a very sensitive semi-nested PCR strategy that was able to detect one leukemic cell in a background of 10 5 bone marrow cells in each patient. This sensitivity was only achieved by the use of different combinations of clonespecific primers complementary to the D-N-J sequence and N-D-N sequence. This demonstrates that great flexibility in the choice of clone-specific primers is necessary to obtain maximal sensitivity and specificity. Using this sensitive PCR strategy, 73% of the patients studied had no detectable residual leukemic cells in the bone marrow on day 43 after the end of induction therapy. This percentage of undetectable MRD is higher than previous studies which reported frequencies of undetectable MRD at the end of induction therapy of 65%, 34 57%, 7 44%, 35 and 25%. 8 Our results contrast with data that show almost all children with ALL have residual leukemia at the end of induction therapy. 9, 10, 36, 37 Those studies used different sources of DNA (stored slides vs fresh purified bone marrow cells), different molecular markers (T cell receptor chain vs immunoglobulin heavy chain gene rearrangements), and varied in their level of sensitivity. In addition to these differences, the intensity of the induction therapy and the time point of bone marrow aspiration are very important for the comparison of different studies. In our study, all children received a highly intensive six-drug induction therapy according to St Jude Total Therapy Studies XII 11 and XIIIA. 12, 13 The four-drug induction therapy consisting of prednisone, vincristine, asparaginase and daunorubicin was reinforced with teniposide (Study XII) or etoposide (Study XIIIA) plus cytarabine according to the Goldie-Coldman hypothesis to increase initial cytoreduction. 1, 38, 39 In contrast, most previous MRD studies were performed at the end of standard induction therapy consisting of only three [8] [9] [10] or four drugs. 7, 36 In our study, bone marrow aspirates were obtained on day 43, 14 days after the end of chemotherapy (day 29). In many previous studies, 8, 35, 37 bone marrow samples were harvested on day 28 immediately at the end of chemotherapy. In those MRD studies it is possible that DNA from dead leukemic cells was amplified whereas, in our study, dead leukemic cells may have been eliminated from the body.
In agreement with previous studies, 7, 8 our results provide strong evidence that the level of MRD after induction therapy in childhood ALL predicts outcome. This correlation could not be made in those studies where almost all children had residual leukemia at the end of induction therapy. 9, 10 In those studies, the authors found that analysis of sequential samples was necessary to predict impending relapse. 9, 10 The cut point of 2 × 10 −5 leukemic cells per bone marrow cell we used to distinguish between a high and a low level of MRD was selected arbitrarily depending on the outcome. Wasserman et al ). This suggests that cut points defining high and low risk will vary depending on the intensity of the induction therapy, the time point of bone marrow aspiration, and the method of detection of MRD.
The level of MRD at the end of induction therapy may be an independent prognostic factor that identifies patients for an increased risk of relapse. A recent study by Brisco et al 40 in adults has provided evidence for an inverse relationship between MRD and remission duration, and although the number of relapsing patients we studied was small, a tendency towards this relationship was also present in our study (Table  1) . No known risk factor had statistical significance for predicting patient relapse, although both age greater than 10 years and initial WBC count were close. Interestingly, of the two patients with 9;22 translocations, patient No. 1 had no detectable MRD at day 43 and remained in complete remission for 75 months, whereas patient No. 25 with the highest level of MRD relapsed at 13 months. Other features which were examined included age, WBC count, DNA index and presence of TEL rearrangement ( Table 3 ). The lack of statistical significance with these risk factors may reflect the small number of patients studied. However, in our study, the level of MRD at day 43 was prognostic of patient relapse with highly statistical significance. Thus, it is possible that those patients with a high level of MRD at the end of induction therapy need a more intensive treatment that includes an early bone marrow transplantation. We feel that the differences between the studies published to date regarding levels of MRD and prediction of treatment outcome represent real differences based on the intensity of the induction therapy and the timing of samples. Thus, differences are due to three-vs six-drug regimens, are due to taking samples immediately following the end of induction therapy vs waiting 2 weeks for hematopoietic recovery, and are perhaps due to differences in sensitivity. Each data set is valid for the particular study, but inter-study comparisons are perhaps not entirely valid because of these differences. We feel that under the conditions that we have used in the current study that MRD levels are highly predictive of treatment outcome. If our findings are confirmed by large prospective studies, it might be useful to stratify patients into high and low risk categories depending on the level of MRD at the end of induction therapy.
